Research Article| Volume 21, ISSUE 9, P1563-1575, September 1999

Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers

      This paper is only available as a PDF. To read, Please Download here.


      The potential mutual interaction between cerivastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, and digoxin was assessed in this nonmasked, nonrandomized, multiple-dose study. The effect of cerivastatin 0.2 mg on mean plasma digoxin levels and the effect of digoxin on the single-dose pharmacokinetics of cerivastatin were assessed in 20 healthy normocholesterolemic men between 18 and 45 years of age weighing 140 to 200 lbs (63.3 to 90.0 kg). Subjects were given a single dose of cerivastatin 0.2 mg. After a 2-day washout period, subjects were given a loading dose of digoxin 0.5 mg for 3 days followed by 0.25 mg daily for 5 additional days (period 1—digoxin alone). Concurrent dosing with cerivastatin 0.2 mg continued for 14 days (period 2—digoxin and cerivastatin), followed by an 8-day course of digoxin-only administration and an optional 6-day extension of digoxin-only treatment for a total of 14 days (period 3). Safety was assessed through physical examination, electrocardiography, laboratory tests, and ophthalmologic examination. Ratio analyses of mean digoxin plasma trough levels, 24-hour urinary digoxin levels, and digoxin clearance with and without concurrent cerivastatin dosing also were carried out. In addition, single-dose pharmacokinetic variables for cerivastatin, including area under the curve (AUC0–24), peak concentration (Cmax), time to peak concentration (Tmax), and elimination half-life (t1/2), were examined with and without concurrent digoxin dosing. Eleven of the 20 subjects completed the entire study. Seven subjects discontinued the study because of treatment-emergent adverse events or laboratory abnormalities that were mostly unrelated to cerivastatin, and 2 subjects were discontinued because of protocol violations. Treatment-emergent adverse events developed in 12 subjects receiving cerivastatin; 11 of these subjects were receiving digoxin concurrently. Six adverse events that led to discontinuation of treatment were unrelated to cerivastatin but were related to digoxin or to a preexisting condition. The most commonly reported event was headache, which occurred with equal frequency compared with placebo groups in large cerivastatin clinical trials. Other events were mild or moderate and resolved without intervention. Mild and transient elevations in hepatic transaminase and creatine kinase values (all <2 times the upper limit of normal) were observed in 7 subjects. After 14 days of concurrent dosing of cerivastatin and digoxin, steady-state digoxin plasma levels, urinary digoxin levels, and urinary digoxin clearance were unchanged compared with steady-state digoxin levels when digoxin was given alone. Compared with dosing with digoxin alone, the AUC0–24, Cmax, and t1/2 for cerivastatin increased 3%, 20%, and 7%, respectively, while the Tmax was reduced by 18% during concurrent treatment with digoxin. These changes are minimal and would not be expected to be clinically relevant. These results demonstrate that when cerivastatin is administered concurrently with digoxin, neither digoxin nor cerivastatin plasma levels are altered. The combination therapy was generally well tolerated.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cheng TO
        Congestive heart failure in coronary artery disease.
        Am J Med. 1991; 91: 409-415
        • Dhalla NS
        • Afzal N
        • Beamish RE
        • et al.
        Pathophysiology of cardiac dysfunction in congestive heart failure.
        Can J Cardiol. 1993; 9: 873-887
        • Gheorghiade M
        • Benatar D
        • Konstam MA
        • et al.
        Pharmacotherapy for systolic dys-function: A review of randomized clinical trials.
        Am J Cardiol. 1997; 80: 14H-27H
        • Eaton CB
        • Feldman HA
        • Assaf AR
        • et al.
        Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension.
        J Fam Pract. 1994; 38: 17-23
        • Clinical Quality Improvement Network Investigators
        Mortality risk, patterns of practice in 4606 acute care patients with congestive heart failure. The relative im-portance of age, sex, and medical therapy.
        Arch Intern Med. 1996; 156: 1669-1673
        • Rodin SM
        • Johnson BF
        Pharmacokinetic interactions with digoxin.
        Clin Pharmacokinet. 1988; 15: 227-244
        • Marcus FI
        Pharmacokinetic interactions between digoxin and other drugs.
        J Am Coll Cardiol. 1985; 5: 82A-90A
        • Brown DD
        • Juhl RP
        • Warner SL
        Effects of hypocholesterolemic interventions on digoxin bioavailability.
        Drug Metab Rev. 1979; 9: 107-117
        • Brown DD
        • Juhl RP
        • Warner SL
        Decreased bioavailability of digoxin due to hypocholesterolemic interventions.
        Circulation. 1978; 58: 164-172
      1. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention.
        Eur Heart J. 1998; 19: 1434-1503
        • Gonzalez ER
        Preventing cardiovascular atherosclerosis: Role of HMG-CoA reductase inhibitors.
        Formulary. 1996; 31: 582-602
        • Hebert PR
        • Gaziano JM
        • Chan KS
        • Hennekens CH
        Cholesterol lowering with statin drugs, risk of stroke, total mortality. An overview of randomized trials.
        JAMA. 1997; 278: 313-321
        • Stein E
        • Sprecher DL
        • Allenby KS
        • et al.
        Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: Effect of 0.2mg/day in subjects with primary hypercholesterolemia.
        J Cardiovasc Pharmacol Ther. 1997; 2: 7-16
        • Insull W
        • Stein E
        • Whalen E
        • Ripa S
        • The Cerivastatin Study Group
        Cerivastatin: A new potent HMG-CoA reductase inhibitor: Efficacy and tolerability in pri-mary hypercholesterolemia.
        J Am Coll Cardiol. 1997; 29: 46A
        • Triscari J
        • Swanson BN
        • Willard DA
        • et al.
        Steady state serum concentrations of pravastatin and digoxin when given in combination.
        Br J Clin Pharmacol. 1993; 36: 263-265
        • Krol GJ
        • Beck GW
        • Ritter W
        • Lettieri JT
        LC separation and induced fluorometric detection of rivastatin in blood plasma.
        J Pharm Biomed Anal. 1993; 11: 1269-1275
        • Krol GJ
        • Beck GW
        • Ritter W
        • et al.
        Determination of rivastatin levels in plasma samples by HPLC and enzyme inhibition assays.
        in: Reid R Wilson ID Biofluid and Tissue Analysis for Drugs, Including Hypolipidaemics. Vol 23. Royal Society of Chemistry, Cambridge1994: 147-156
        • Gibaldi M
        • Perrier D
        Pharmacokinetics. Marcel Dekker, New York1980: 293-300
      2. Data on file, Study X31-091.
        Bayer Corporation, West Haven, ConnMay 1996
        • Deslypere JP
        Clinical implications of the biopharmaceutical properties of fluva-statin.
        Am J Cardiol. 1994; 73: 12D-17D